Study identifies antidepressants that get patients well and keep them well

Coverage from Tech Times, Everyday Health, and Workers' Liberty reports on a new study identifying antidepressants that get patients well and keep them well. According to Tech Times, Lexapro outperformed Prozac for long-term depression in what the outlet describes as the largest study to date, and the second-ranked drug is not available in the US. Everyday Health frames the research as offering an answer to the question of which antidepressant is most effective. Workers' Liberty publishes a piece titled "Blunder on antidepressants," suggesting critical commentary on how the findings are being handled or interpreted. The coverage does not yet specify the study's authors, institutions, sample size, duration, or exact ranking of medications beyond Lexapro and Prozac. It also does not state whether the second-ranked drug is approved elsewhere or why it is unavailable in the US market. The emphasis across outlets is on comparative effectiveness and long-term outcomes rather than short-term symptom relief. Readers seeking context should note that antidepressant selection typically involves balancing efficacy, side effects, cost, and availability, and that a single study does not establish clinical guidelines. What to watch next depends on whether regulators, prescribers, or professional bodies respond to the findings, and whether the second-ranked drug's availability changes. Coverage does not indicate any announced trials, policy reviews, or prescribing changes at this time.